One deal, many MOR antibodies

Back to the Future

MorphoSys AG expects its new 10-year deal with Novartis AG to be transformational, providing the antibody technology company with the financial security and strategic flexibility to drive its development as an independent drug company while marking an end of its need to continually find new partners for its platform technologies. For Novartis, the deal will provide a core capability that will enable it to develop biologics in-house, freeing it from its past reliance on in-licensing...